The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

First Pediatric Triple Organ Transplant Saves Young Girl's Life

Back to News Homepage

Next

Egyptian Hep C Problem to Benefit from Better Test

Hepatitis C Phase 3 Trials Underway for TMC435

March 13, 2012

Print this page

In two separate Phase 3 trials, Hepatitis C patients with genotypes 1 and 4 are being treated with TMC435 plus pegylated interferon and ribavirin.

Medivir Announces New Studies in Phase III Program for TMC435

HUDDINGE, Sweden, March 13, 2012 /PRNewswire via COMTEX/ — Study in previous non-responder Hepatitis C genotype-1 infected patients

Study in Hepatitis C genotype-4 infected patients

MedivirAB (omx:MVIR) a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

Continue reading this entire article:

http://www.marketwatch.com/story/medivir-announces-new-studies-in-phase-iii-program-for-tmc435-2012-03-13

No Comments - be the first!
Share
Share

Previous

First Pediatric Triple Organ Transplant Saves Young Girl's Life

Back to News Homepage

Next

Egyptian Hep C Problem to Benefit from Better Test

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.